Institut du Cerveau et de la Moëlle Épinière – myBrain Technologies presents positive results of Neurorelax study

December 4, 2019 — myBrain Technologies, a company specializing in neuro-technological solutions to improve the quality of life and well-being of people, announces the positive results of the first part of its Neurorelax study, conducted in collaboration with the ICM – Institut du Cerveau et de la Moelle Epinière in Paris.

The clinical study Neurorelax, longitudinal, randomized, double-blinded is composed of a group that performs thetraining with real neurofeedback (NF) melomind, and a second group called “mock neurofeedback” or placebo that performs training based on realistic false neurofeeback. The study was carried out on 34 subjects in two contexts experimental: the first “Supervised” in the laboratory, the second “Semi-supervised” in the company.


The main objective of the Neurorelax was to characterize the effects of long-term neurofeedback, analyzed from two perspectives: thehe learning performance and the benefits above all electro-physiological électro (changes in neural responses), then behavioural (increase in the perceived level of relaxation).
Here are the main results:
1 – Evaluation learning (through the sessions d’training) Neurorelax shows that subjects who performed “true NF” were able to increase thee based on alpha brain waves significantly compared to the placebo group. This positive learning is found in both contexts, Supervised (p<0,05) et Semi- supervisé (p<0,001), montrant ainsi la réalisabilité de cet effet et la robustesse de la procédure de NF dans différents areas of usein an optimal learning time window. The main results for this first part of the study validate the possibility to perform neurofeedback from recordings by reduced mobile EEG device with 2 dry electrodes (melomind™).
2 – Evaluation of the benefits of neurofeedback with melomind™(outside of the training sessions)’training) In order to assess the benefits of NF, the study has measured mesuré the impact of this learning on basal alpha activity outside of thepractices. A significant increase in the level of on air alpha was found only in participants who achieved true NF. This result was observed in both experimental settings Semi-supervised (p<0<0,015) et Supervisé (p.027).Neurorelax shows benefits at the electrophysiological level, with a significant increase in the level of of waves alpha at rest, via the practice of neurofeedback. From a perceptual point of view, a significant increase in the level of relaxation felt after the exercise was completed was observed.s theNF training was shown in both experimental contexts, with 28% in the Semi-supervised context and 10% in the Supervised context.
According to Dr. Nathalie George, Director of Research CNRS at the ICMs main partner, the main partner of the NeuroRelax. ” This first phasee of recording and analysiss of Neurorelax, shows very encouraging results that allow d’open opportunities for use dry electrode neurofeedback, out of the hospital setting “».
For Yohan Attal, CEO & Co-CEOfounder of MyBrain.”The results obtained in this first phase of Neurorelax are as follows an important milestone for MyBrain Technologies. We show today, based on evidence scientists, thatmelomind™, uh, our solution of brain training has the potentiel to provide an alternative to existing solutions aimed at improving the management of stress-related disorders”.
The extension of the Neurorelax is going to happenr current 2020 at the ICM.